SUNNYVALE, Calif., Dec. 17, 2010 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that the company has established a Medical Affairs function to accelerate CyberKnife data collection, utilization and referral patterns and to provide strategic guidance on clinically driven processes, innovations and initiatives.
Since the company’s inception in 1990, Accuray has been focused on driving innovation that meets the unique needs of clinicians and patients as part of its corporate strategy to improve patient care across various cancers and indications. With more than 500 peer-reviewed publications supporting the use of CyberKnife radiosurgery, Medical Affairs will continue to further medical research through the development and support of clinical studies and protocols globally, while also strengthening relationships with key opinion leaders and academic centers worldwide.
“We are very proud to announce the formation of Medical Affairs, which demonstrates another positive step in our ongoing strategy toward clinically driven research and development, innovation and customer support,” said Euan S. Thomson, Ph.D., president and CEO of Accuray. “Because we are changing clinical practice, we believe this function will play a vital part in supporting our customers in their adoption, utilization and medical research and will be pivotal in helping establish the clinical applications of the future.”
Omar Dawood, M.D., M.P.H, a surgeon and radiologist by training who has led Accuray’s Clinical Development team over the past three and a half years, will lead the Medical Affairs function, and will report in to Euan Thomson, Accuray’s CEO. The organization will focus on understanding the needs of clinicians worldwide and supporting their efforts to advance the field of radiosurgery and improve patient care.
About the CyberKnife® Robotic Radiosurgery System
The CyberKnife Robotic Radiosurgery System is the world’s only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.
About Accuray
Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 100,000 patients worldwide and currently more than 215 systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit www.accuray.com.
Safe Harbor Statement
The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, including statements relating to market acceptance and clinical acceptance are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management’s good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: market acceptance of products, clinical acceptance and other risks detailed from time to time under the heading “Risk Factors” in our report on Form 10-K for our 2010 fiscal year, our form 10-Q filed on November 8, 2010 and our other filings with the Securities and Exchange Commission. The Company’s actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.
Available Topic Expert(s): For information on the listed expert(s), click appropriate link.
Omar Dawood, M.D., MPH
https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=85068
SOURCE Accuray Incorporated
